BioMarin Refreshes Its Pipeline With ZyStor Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
In a deal weighted heavily toward downstream payments, the orphan drug maker gains a compound that could challenge Genzyme in Pompe disease.